Patient Perspectives on Barriers to Diagnosis and Treatment of Tardive Dyskinesia from a Cross-sectional Survey (P4-5.018)
Gianni Solis, Nayla Chaijale, Alma Patricia González, Di Zhang et autres
0 citationsNeurology
Verena Ramirez-Campos
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
31Publications signalées
43Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Migraine and Headache StudiesFibromyalgia and Chronic Fatigue Syndrome ResearchHealth Systems, Economic Evaluations, Quality of LifeTrigeminal Neuralgia and TreatmentsSuicide and Self-Harm Studies
Publications récentes
EE353 Cost-Consequence Analysis of Fremanezumab Treatment in Patients With Migraine and Comorbid Major Depressive Disorder in the UK Using Results From the UNITE Study
DD Mitsikostas, Alain Morel, Verena Ramirez-Campos, MT Driessen
0 citationsValue in Health
PND61 Adverse Event Profiles of Therapies That Target the Calcitonin GENE-Related Peptide (CGRP) Pathway, during the First SIX Months after Launch: A Real-World DATA Analysis Using the FDA Adverse Events Reporting System (FAERS)
Stephen D. Silberstein, Shoshana Reshef, Joshua M. Cohen, Sanjay Gandhi et autres
1 citationValue in Health
Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study
Dawn C. Buse, Sanjay Gandhi, Joshua M. Cohen, Verena Ramirez-Campos et autres
22 citationsThe Journal of Headache and Pain
PND89 CLINICAL, ECONOMIC AND HUMANISTIC OUTCOMES OF PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE ACCORDING TO THEIR LEVEL OF PATIENT ACTIVATION IN THE USE
H. Benhaddi, Verena Ramirez-Campos, L. Lee
0 citationsValue in Health
PND106 PATIENT-REPORTED OUTCOMES TO ASSESS SYMPTOMS AND EFFECTS ACROSS ALL 5 PHASES OF MIGRANE
J.H. VanderPluym, Verena Ramirez-Campos, Ana Paula Bidutte Cortez, Jack Cohen et autres
0 citationsValue in Health
Clinically Meaningful Responses to Fremanezumab in Patients With Migraine and Documented Inadequate Response to 2–4 Migraine Preventive Medication Classes in the Open–label Period of the International, Multicenter Phase 3b FOCUS Study (4398)
Jonathan P. Gladstone, Xiaoping Ning, Joshua M. Cohen, Verena Ramirez-Campos et autres
1 citationNeurology
Efficacy of Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2–4 Migraine Preventive Medication Classes: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study (4240)
Stephen D. Silberstein, Joshua M. Cohen, Verena Ramirez-Campos, Ronghua Yang et autres
2 citationsNeurology
Burden of Comorbid Depression and Anxiety on Migraine-specific Health-related Quality of Life in Adult Migraine Patients in the United States (4438)
Dawn C. Buse, Ravi Iyer, Joshua M. Cohen, James Jackson et autres
2 citationsNeurology
Safety and Tolerability of Fremanezumab in Patients With Episodic and Chronic Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medications: Results From the Open-label Period of the Phase 3b FOCUS Study (4622)
David Kudrow, Joshua M. Cohen, Verena Ramirez-Campos, Ronghua Yang et autres
0 citationsNeurology
Assessment of the Patient Experience Across All Phases of Migraine (4636)
Juliana H. VanderPluym, Verena Ramirez-Campos, Alma Cortez, Joshua M. Cohen et autres
0 citationsNeurology
Impact of Fremanezumab on Headache-related Disability in Patients With Migraine and Documented Inadequate Response to 2–4 Classes of Migraine Preventive Medication Classes in the Open–label Extension of the Phase 3b FOCUS Study (4416)
Amaal J. Starling, Verena Ramirez-Campos, Xiaoping Ning, Joshua M. Cohen et autres
0 citationsNeurology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.